Beacon Pharmaceuticals PLC — Company profile

Pharmaceutical Preparations · Bangladesh

Last price 92.7 BDT (At close: Oct 29, 2026) · Market cap 21.41B

Latest research: Beacon Pharmaceuticals valuation report: fair value BDT 22–88.1 (Oct 2026) · Beacon's profit doubled in FY2026, but 16% long-run returns support a fair value range of BDT 22–88 (base 52)

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Technical report: trend, RSI, support and resistance, charts

Company profile

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories such as oncology, hematology, anti-cancer, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointestinal, infectious diseases, immunology, rheumatology, muscle relaxants, antihistamines, anti-coagulants, protein supplements, pediatrics, NSAIDs, nutritional supplements, and others. In addition, the company offers contract and toll manufacturing services. It provides its products under the Pemro, Nivomab, Xelpac Premium, Docexan, Xaloplat Aqua, Gemoxen Aqua, ETP, FXR, Renesis, Mezest, Eposis, Tirza, Xelmet, Xerova, Sinjard, Ovocal, Haxinor, Tetrazin, Lubilux, Paloxi, Olonex, Gaviflux, Mirogab, Flexibac, and Bukof brand name. Beacon Pharmaceuticals PLC was incorporated in 2001 and is based in Dhaka, Bangladesh.

Details

Key executives

Contact